Skip to Content
Merck
All Photos(1)

Key Documents

SML3695

Sigma-Aldrich

Sabutoclax

new

≥98% (HPLC)

Synonym(s):

(1R)-1,1′,6,6′,7,7′-Hexahydroxy-3,3′-dimethyl-N5,N5′-bis[(2R)-2-phenylpropyl]-[2,2′-binaphthalene]-5,5′-dicarboxamide, (RS)-1,1′,6,6′,7,7′-Hexahydroxy-3,3′-dimethyl-N5-((R)-2-phenylpropyl)-N5′-((R)-2-phenylpropyl)-2,2′-binaphthyl-5,5′-dicarboxamide, BI-97C1, BI97C1

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C42H40N2O8
CAS Number:
Molecular Weight:
700.78
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

shipped in

wet ice

storage temp.

-10 to -25°C

SMILES string

O=C(C1=C(O)C(O)=CC2=C(O)C(C3=C(C)C=C4C(C(NC[C@@H](C5=CC=CC=C5)C)=O)=C(O)C(O)=CC4=C3O)=C(C)C=C12)NC[C@@H](C6=CC=CC=C6)C

Biochem/physiol Actions

Potent inhibitor against antiapoptotic Bcl-2 family proteins (Bcl-xL, Bcl-2, Mcl-1, Bfl-1) with anti-cancer efficacy in cultures and in vivo.



Sabutoclax (BI-97C1) is a potent inhibitor against antiapoptotic Bcl-2 family proteins (IC50 in nM against BH3 peptide binding = 310/Bcl-xL, 320/Bcl-2, 200/Mcl-1, 620/Bfl-1) that induces apoptosis in cancer cultures (EC50 in nM = 49/BP3, 130/PC3, 420/H460) with little cytotoxicity against bax-/-bak-/- cells. Sabutoclax anti-tumore efficacy in vivo, including a Bcl-2 transgenic model (42 mg/kg i.p. in mice expressing human Bcl-2 in splenic B-cells) and a M2182 prostate cancer xenograft model (1,3, 5 mg/kg q.o.d. i.p. in mice).

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Belal Azab et al.
Journal of cellular physiology, 227(5), 2145-2153 (2011-07-23)
Adenovirus (Ad)-based gene therapy represents a potentially viable strategy for treating colorectal cancer. The infectivity of serotype 5 adenovirus (Ad.5), routinely used as a transgene delivery vector, is dependent on Coxsackie-adenovirus receptors (CAR). CAR expression is downregulated in many cancers
Jun Wei et al.
Journal of medicinal chemistry, 53(10), 4166-4176 (2010-05-07)
In our continued attempts to identify novel and effective pan-Bcl-2 antagonists, we have recently reported a series of compound 2 (Apogossypol) derivatives, resulting in the chiral compound 4 (8r). We report here the synthesis and evaluation on its optically pure
Ju Wang et al.
Translational neurodegeneration, 10(1), 12-12 (2021-04-02)
Currently, there is no cure for Alzheimer's disease (AD). Therapeutics that can modify the early stage of AD are urgently needed. Recent studies have shown that the pathogenesis of AD is closely regulated by an endo/lysosomal asparaginyl endopeptidase (AEP). Inhibition

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service